Inside 340B Report

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including the comments submitted to the Health Resources and Services Administration (HRSA) in response to the agency's 340B rebate request for information (RFI); what Congress and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. had to say about 340B rebates and the program, in general; and key legal developments with major 340B implications. Key Topics Covered: Rebate RFI Wraps Up Will breaks down the avalanche of responses to HRSA's RFI seeking comments on whether to implement a future 340B rebate model leading up to the agency's April 20 deadline. He notes that the submissions came against the backdrop of federal court rulings that blocked HRSA's initial 340B rebate pilot proposal from taking effect Jan. 1, as many providers and manufacturers were likely writing their comments anticipating a potential future legal challenge if HRSA attempts to implement a new rebate model. Congress and Kennedy on Rebates  Luke and Will discuss competing letters circulating in Congress relating to a potential federal 340B rebate model. Shannon discusses what appeared to be Kennedy's first public comments on 340B rebates, which came during a series of Capitol Hill appearances he made on the Trump administration's fiscal year 2027 HHS budget proposal. Shannon also highlights the secretary's criticism of how some 340B hospitals use program savings, as well as praise he shared for the program while fielding lawmakers' questions. Luke talks about a Senate committee hearing on drug pricing at which a witness pushed to end the 340B program's current structure and replace it with a direct subsidy program. Key Legal Developments Will breaks down a Richmond, Va.-based federal appeals court's 2-1 decision against Maryland's 340B contract pharmacy access law. He notes that the same three judges on the Maryland case also recently decided against West Virginia's similar 340B contract pharmacy access law. Will explains that those two decisions were the first appellate rulings to side with manufacturers, after three-judge federal appeals court panels unanimously upheld similar laws in Arkansas, Louisiana and Mississippi. Ted and Will also discuss whether the appeals court will grant West Virginia officials' recent request for a full panel rehearing. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Visante partners with health systems to deliver confidence in 340B—through deep experience, rigorous compliance and relentless focus on program compliance. We are very grateful to Visante for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including the wave of identical responses to the Health Resources and Services Administration's (HRSA) 340B rebate request for information (RFI), the Trump Administration's renewed proposal to shift oversight of the 340B program to another federal agency and key legal developments with major 340B implications. Key Topics Covered: Duplicate 340B Rebate RFI Responses Will breaks down early stakeholder responses to the HRSA's 340B rebate RFI, which the agency issued just days after withdrawing its previous 340B rebate pilot. He notes that more than half of the initial responses were identical submissions closely mirroring a template from Patients Rising, a patient group that lists more than a dozen large drugmakers among its corporate sponsors. Will notes that hours after 340B Report broke news on the submissions, Patients Rising said it was ending work with the third-party firm it hired for RFI outreach. Trump's New Budget and Tariffs  Shannon discusses the Trump administration's proposed fiscal year (FY) 2027 Health and Human Services Department budget and what it means for the 340B program. She notes that the HHS spending proposal revives previous plans to restructure HRSA and move the 340B program to the Centers for Medicare and Medicaid Services, as well as calls for a major increase in 340B funding. Luke offers insights into how Congress could approach FY 27 funding legislation—including an effort to attach language barring a 340B rebate model. Luke also breaks down the White House's latest plans to implement tariffs on pharmaceutical products. Key Legal Developments Shannon discusses the implications of a recent Washington, D.C. federal district court ruling that struck down a 2013 HRSA policy that restricts how certain 340B hospitals can purchase initial drug inventory. Will breaks down drugmaker AbbVie's new lawsuit challenging HRSA's 340B patient definition, including the history of the agency's definition and what the legal outcome could mean for the 340B program's future. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce is the only third party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. Learn more at www.thepharmaforce.com. We are very grateful to PharmaForce for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and 340B Report's national correspondent Luke Zarzecki break down the latest in 340B news, including 340B stakeholder reactions to a provider hearing in the U.S. House and ongoing discussion over a 2027 fiscal year (FY) federal spending package that could include language blocking 340B rebates. The team also discusses major updates in the states, including a newly enacted first-of-its-kind 340B law in the Pacific Northwest, a controversial effort to kill a 340B bill in the Midwest and a closer look into state prescription drug affordability boards (PDABs). Key Topics Covered: Capitol Hill Update Shannon and Luke discuss a recent House Energy & Commerce (E&C) Health Subcommittee hearing on providers' role in health care costs, which focused on the 340B program, among other things. Shannon breaks down what two of the witnesses had to say about the drug discount program. Luke highlights the questions key lawmakers asked witnesses, as well as how two senior Republican committee members called for 340B reforms and support for their 340B ACCESS Act, which has drawn major pushback from provider groups. Shannon also offers an update on the FY 2027 federal appropriations process taking shape on Capitol Hill, noting that a group of bipartisan House lawmakers is pushing to add language to the health spending bill that would block a 340B rebate model's implementation. Key State Developments Will discusses "the tale of two states," where high-profile 340B bills in Washington and Kansas faced very different outcomes. He also discusses two recent federal district court rulings in favor of state contract pharmacy laws, which continued a string of mostly favorable legal rulings for the states. Deep Dive into PDABs Luke discusses PDABs that are popping up across the states and their potential implications on the 340B program. At least 11 states have created a PDAB or a similar board tasked with addressing high drug prices, with some states granting that board to set upper payment limits on drugs. Luke shares why experts say PDABs could lead to lower 340B savings for covered entities, as well as other impacts on the drug supply chain.  Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Proximity is the 340B revenue operations platform built to bring control back to your program. Proximity unifies and normalizes TPA, pharmacy, EHR, wholesaler and payer data into a single system—so issues can be identified, corrected and resolved across the full claim lifecycle. To learn more, reach out to [email protected]. We are very grateful to Proximity for its sponsorship.  Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and 340B Report's national correspondent Luke Zarzecki break down the latest in 340B news, including a key U.S. House subcommittee's upcoming provider hearing and a leadership shakeup that could affect the bipartisan U.S. Senate 340B working group. The team also discusses reactions to another major drugmaker's plan to require 340B in-house pharmacy data reporting, major 340B related-developments in two federal court cases and divergent state 340B program bills on the cusp of becoming law. Key Topics Covered: Capitol Hill Update Shannon and Luke discuss the latest 340B developments on Capitol Hill. Shannon previews the House Energy and Commerce (E&C) Health Subcommittee's March 18 hearing that will look at the role providers play in rising health care costs. She notes that while the hearing will not specifically focus on the 340B program, the issue is likely to arise with the American Hospital Association—which successfully blocked the Trump administration's 340B rebate pilot from taking effect—among those slated to testify. Shannon also highlights E&C Committee Chairman Brett Guthrie's (R-Ky.) reintroduction of a bill, which calls for a study of how value-based purchasing arrangements affect the 340B program. Luke talks about what the change in guard at the Department of Homeland Security could mean for the bipartisan 340B Senate working group, after President Donald Trump nominated U.S. Sen. Markwayne Mullin (R-Okla.) to take over for DHS Secretary Kristi Noem.  Claims Data Pushback Will discusses Novo Nordisk's recent announcement that it plans to require covered entities to submit claims data for 340B utilization at in-house pharmacies in order to access 340B pricing. He explains why Novo's policy, which is similar to one Eli Lilly announced earlier this year, marks a significant expansion of reporting requirements. Meanwhile, Luke breaks down what provider groups and pharmaceutical stakeholders have said about the new requirements, and the actions they have taken in response to them. Key Court Rulings Shannon, Will and Ted discuss two recent federal court rulings that have major 340B implications. Shannon shares how a Washington D.C. federal district court's order striking down the Health Resources and Services Administration's (HRSA) contentious 340B hospital offsite clinic registration policy is a major win for hospitals. Ted provides historical context on the case and why hospitals sued HRSA over the policy. Will discusses the federal government's latest amicus briefs backing drugmakers in legal challenges to state 340B contract pharmacy access laws, and how the unexpected move could potentially impact ongoing litigation. State Legislative Activity Will discusses Washington's state 340B contract pharmacy access legislation, which also includes both provider and drugmaker reporting requirements, that's awaiting action from Gov. Bob Ferguson (D). He also dives into Virginia's unsuccessful efforts to pass contract pharmacy access legislation after lawmakers amended an earlier contract pharmacy bill to replace it with a work study group. Ted explains why he was surprised that Virginia did not enact a 340B contract pharmacy access law despite early momentum in the state capitol and a newly elected governor who has been a longtime 340B advocate. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This week's episode is sponsored by CompassRx, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. We are very grateful to CompassRx for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and Luke Zarzecki, 340B Report's national correspondent, break down the latest in 340B news, including the Trump administration's high-profile entrance into the fight over state 340B contract pharmacy access laws. The team also discusses updates in the federal government's consideration of a potential new 340B rebate pilot, President Donald Trump's recent calls to codify most-favored nation (MFN) pricing agreements and the 340B Coalition's winter conference and National Association of Community Health Centers' (NACHC) Policy & Issues Forum.   Key Topics Covered:   Contract Pharmacy Restrictions Fight Heats Up Will discusses the Trump administration's unexpected move to file amicus briefs supporting two drugmaker legal challenges to state 340B contract pharmacy access laws in Colorado and Rhode Island. He explains that most federal court rulings on contract pharmacy access laws have sided with the states, noting it is unclear to what extent the federal government's briefs will affect this trend. Will also notes that two U.S. Justice Department lawyers who signed the briefs previously represented drugmakers in drug pricing litigation, including one who served as a drugmaker's counsel in cases on 340B contract pharmacy use and 340B rebates.   Rebate Model Update Luke, Shannon and Will discuss the latest developments in the federal government's consideration of a potential new 340B rebate model after court action halted the initial pilot from taking effect. They break down the latest regulatory actions surrounding that effort, including the White House's Office of Management and Budget's review of a prerule and the Health Resources and Services Administration's (HRSA) subsequent issuance of a request for information and an information collection request—and how stakeholders have responded to them. Will offers insights into what HRSA's possible new rebate model could look like based off of these documents.   MFN Codification Push Shannon highlights the Trump administration's recent push to codify MFN principles into federal law, including the president's State of Union call for Congress to pass such legislation and Centers for Medicare and Medicaid Services Administrator Mehmet Oz's similar comments during a Pharmaceutical Research and Manufacturers of America (PhRMA) forum. She notes pushback such efforts have garnered from PhRMA, which has instead urged lawmakers to focus on reforming pharmacy benefit managers and the 340B program.   Conference Recaps Will shares his key takeaways from the Winter 340B Coalition Conference in San Diego, including provider concerns with manufacturer actions they argue are threatening the 340B program. He also discusses health policy experts' takes on the program, including what to expect from Congress and the Trump administration in the coming months. Luke discusses HRSA Administrator Tom Engels' comments at NACHC's forum.   Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship.    Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and Luke Zarzecki, 340B Report's new national correspondent, break down the latest in 340B news, including 340B legislative developments on Capitol Hill and statehouses—and the role of dark money campaigns trying to shape the message. The team also discusses the Health Resources and Services Administration's major decision to formally withdraw its 340B rebate model pilot and what that could mean for the future of drugmaker-backed efforts to pursue 340B rebates.    Key Topics Covered: Capitol Hill Happenings Shannon, Luke and Will highlight the latest 340B-related happenings in Congress. Shannon discusses a new bipartisan U.S. House bill that aims to prevent federally qualified health centers from being included in any 340B rebate models and previews a yet-to-be introduced bill that would expand similar protections to other 340B covered entities, but not major hospitals. Luke provides an update on the bipartisan U.S. Senate group working on the SUSTAIN 340B Act, including what the final legislation could look like and the reported issues stalling its introduction. Shannon also offers a recap of the recently enacted federal spending package and how it's expected to affect 340B stakeholders. Meanwhile, Will discusses Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy's (R-La.) recent inquiries into 340B prime vendor Apexus as part of his broader probe into the 340B program. Rebate Model Update Will discusses the federal government's recent filing formally withdrawing its controversial 340B rebate pilot proposal and agreeing to new procedural guardrails if it attempts to implement a different 340B rebate model in the future. He then details the hospital lawsuit that led federal courts to block implementation of the 340B rebate pilot before it took effect on Jan. 1. Will also discusses what the outcome of this litigation could mean for the future of 340B rebates.  States Eye 340B Bills   Will shares new developments from statehouses in Illinois, Michigan, Kansas and Virginia, where lawmakers are considering 340B contract pharmacy access legislation, 340B provider reporting bills—or both. He also breaks down 340B Report's recent coverage of the tactics of new dark multiple new money efforts opposing 340B contract pharmacy legislation in multiple states. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. We are very grateful to VytlOne for its sponsorship.  Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, Associate Editors and Senior Writers Shannon Young and Will Newton join Luke Zarzecki, 340B Report's new national correspondent, in breaking down the latest in 340B news, including the Department of Health and Human Services' (HHS) move to officially drop its appeal in a case that halted the 340B rebate pilot program and a new federal spending bill that includes funding for key departments overseeing the 340B program, as well as for community health centers. They also discuss new drugmaker 340B contract pharmacy and maximum fair price (MFP) policies, and Luke introduces himself. Key Topics Covered: Rebate Case Update Will provides the latest on the 340B rebate debate, including HHS' decision to drop its appeal of a Maine federal judge's injunction halting the agency's 340B rebate pilot program. That means HHS still cannot implement its 340B rebate pilot as originally planned. But, as Will notes, it does not mean the broader debate over 340B rebates is settled. He shares that attorneys who have represented both 340B providers and the drug industry do not expect drugmakers or HHS to abandon their efforts to pursue 340B rebate models. Federal Funding Package Shannon and Luke break down a new bipartisan congressional health care package and what it could mean for the 340B program. Shannon discusses a U.S. House-approved spending bill and how much it allocated for key agencies that oversee the 340B program. She also details the highly anticipated funding figures for community health centers, which are largely funded by the federal government, and notes that it doesn't include a Trump administration proposal to move 340B program oversight from the Health Resources and Services Administration to the Centers for Medicare and Medicaid Services. Luke discusses the pharmacy benefit manager (PBM) reform provisions included in the legislation and their 340B implications. Shannon also notes that congressional leaders, who authored the appropriations bill, signaled concerns with the 340B rebate pilot program and requested an update from HRSA within one month in a bipartisan document released in conjunction with the spending package. Drugmaker Policies Will and Shannon discuss recent drugmaker policy developments. Will details Eli Lilly's new policy that would require all covered entities to submit claims data on 340B utilization at in-house pharmacies in a major shift that drew strong provider backlash. Shannon discusses Johnson & Johnson's interim plan to address "deduplication" between 340B discounts and the MFP without the 340B rebate pilot. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton in breaking down the latest in 340B news, including a Maine federal judge's ruling that halted the government's 340B rebate model pilot rollout—and subsequent appeals court actions. They also discuss what 340B stakeholders can expect from statehouses and Congress on the legislative front in 2026. Key Topics Covered: Rebate Pilot Paused Shannon, Will and Ted provide an overview of the American Hospital Association's lawsuit challenging the Department of Health and Human Services and Health Resources Administration's 340B rebate model pilot program, which was set to begin on Jan. 1. Shannon breaks down the Dec. 19 oral arguments held in Portland, Maine, that she covered, while Will discusses the judge's decision to temporarily halt the program and the government's efforts to appeal the ruling. Ted offers perspectives on how the litigation could unfold in the coming months and its implications. Actions in Another 340B Rebate Case Will provides an update on separate 340B rebate-related litigation before a Washington, D.C. federal appeals court. He explains why this case, which deals with broader legal questions about statutory authority over 340B rebates, is different from the hospital lawsuit in Maine, which is an administrative law case dealing specifically with the government's 340B rebate pilot. 2026 Legislative Agenda Shannon discusses what 340B stakeholders can expect to see on Capitol Hill in 2026, including U.S. Rep. Brett Guthrie's (R-Ky.) recent comments about prescription drug policy reforms at an early January GOP retreat. Will breaks down the latest 340B legislative activity in multiple statehouses, including the first contract pharmacy access bills of 2026 in Washington and Florida, as well as the growing number of provider reporting bills expected in the coming year. Subscribe & Stay Updated: How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Follow Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Verity Solutions. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton breaking down the latest in 340B news, including a new hospital lawsuit aiming to block the Health Resources and Services Administration's (HRSA) 340B rebate pilot, HRSA's recent webinar about that program, key regulatory updates on Medicare negotiated drug prices and a finalized hospital outpatient rule with significant implications for 340B hospitals and other stakeholders. Key Topics Covered: Hospitals Continue to Oppose Rebate Pilot Will breaks down a hospital group's new lawsuit urging a Maine federal district court to block HRSA from implementing its 340B rebate pilot ahead of its Jan. 1, 2026 launch. He also provides an update on separate 340B rebate litigation before a Washington, D.C. federal appeals court. Shannon highlights a new letter from a different national hospital group urging HRSA to address key concerns with the pilot. Technical Issues Disrupt HRSA's Rebate Webinar Will explains the technical issues that hampered HRSA's highly anticipated Dec. 4 webinar on its 340B rebate pilot program, preventing many stakeholders from joining. He then shares details of the second half of HRSA's webinar that 340B Report was able to access and notes 340B Report will provide additional coverage of the full webinar once it becomes available. CMS Lists New Negotiated Medicare Prices, Finalizes OPPPS Rule Shannon breaks down the Centers for Medicare and Medicaid Services' (CMS) late-November release of  the "maximum fair price" (MFP) it will pay for 15 high-cost Medicare Part D drugs starting in 2027, and how those negotiated prices are expected to compare to the drugs' 340B ceiling prices. She and Ted also discuss 340B provider advocates' concerns with CMS' finalized 2026 Hospital Outpatient Prospective Payment System (OPPS) rule, which includes a Medicare drugs acquisition cost survey and plan to accelerate outpatient payment cuts to offset previous 340B hospital lump sum repayments. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by PharmaForce. PharmaForce is the only third party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) approval of the final drugmaker 340B rebate pilot plan; oral arguments in a key federal court case centered on 340B rebates; and Kalderos' official entrance into the 340B contract pharmacy claims clearinghouse space. Key Topics Covered: Final Rebate Pilot Model Plans Approved, Additional Details Unveiled Will provides an in-depth look at HRSA's recent approval of Novartis' 340B rebate plan for Entresto—the final drug eligible for the upcoming  pilot program. He also explains provider concerns about the pilot's rollout—including how manufacturers and their vendor defined the claims data field "340B ID"—and HRSA's response seeking to quell those concerns. Appeals Court Hears Oral Arguments in Rebate Case Will discusses oral arguments he attended at a Washington, D.C., federal appeals court that could shape the future of 340B rebates, including HRSA's rebate pilot. Attorneys for the drug industry, the federal government and trade group 340B Health debated who—if anyone—has authority to decide whether drugmakers can offer 340B pricing through a rebate. Will notes that all three sides faced tough questioning from the judges, who appeared well-versed in the nuances of the 340B program. 1st Drugmaker Transitions to Kalderos' Truzo Platform Shannon breaks down the significance of drugmaker Alkermes' recent decision to transition its 340B contract pharmacy policy administration from Second Sight Solutions' 340B ESP platform to Kalderos' Truzo clearinghouse—making it the first drug manufacturer to do so. She also discusses the pushback the Alkermes' short timeline for the shift, which will go live Dec. 1, drew from 340B provider advocates. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs, and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) recent approval of drugmaker 340B rebate pilot plans—and the reactions they sparked; major court actions affecting Oklahoma and Colorado's 340B contract pharmacy access laws; and what Abigail Spanberger's (D) Virginia gubernatorial win could mean for 340B policy in that state. Key Topics Covered: Rebate Pilot Model Plans Approved, Unveiled Will provides an in-depth look at the manufacturer rebate pilot plans that HRSA approved, as well as provider frustrations over the pilot's rollout. Shannon breaks down the contrasting reactions to HRSA's plan approvals. 340B providers panned the move and the drug industry embraced it, urging that the model be expanded. She also teases a Dec. 15 340B Report subscriber-only webinar that will focus on the rebate pilot model's implementation.  Federal Courts Block Oklahoma's Contract Pharmacy Law, Back Colorado's Will discusses a pair of conflicting federal district court rulings on 340B contract pharmacy access laws in two states. One judge blocked Oklahoma from enforcing its law while the drug industry litigation plays out, while a different judge denied AbbVie's bid to block enforcement of Colorado's statute. Despite the Oklahoma federal court's ruling, Shannon notes that some drugmakers are exempting covered entities in that state from their contract pharmacy restrictions. Virginia's Gubernatorial Election Implications Shannon breaks down how Spanberger's recent gubernatorial win could bolster advocates' efforts to enact 340B contract pharmacy protections in Virginia. She and Ted discuss Spanberger's leadership on 340B issues in Congress and how the Democrat made prescription drug pricing a key tenet of her 2025 campaign for governor. They also compare Spanberger's actions on 340B to outgoing Gov. Glenn Youngkin (R), who vetoed a widely supported, bipartisan 340B contract pharmacy access bill in 2024 after pressure from a dark-money group. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. We are very grateful to VytlOne for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Senate Health, Education, Labor and Pensions (HELP) Committee's recent hearing on 340B, key takeaways from the 340B Grantees Fall Conference in Atlanta and 340B Report's recent webinar on the Health Resources and Services Administration's (HRSA) 340B rebate pilot and where we may be headed next on that controversial proposal. Key Topics Covered: Senate HELP Committee Mixes 340B Criticisms and Support Shannon and Will provide an in-depth look at the Senate HELP Committee's Oct. 23 hearing on the 340B program, which occurred despite an ongoing federal government shutdown. Shannon discusses the dark money anti-340B campaign now underway in Washington, D.C., and how many provider advocates were pleasantly surprised about how the hearing went. Will explains that while HELP Committee Chair Bill Cassidy (R-La.) reiterated familiar 340B criticisms, many lawmakers from both parties defended the program's importance to providers. He also notes that the hearing often veered off topic, with many Democrats criticizing the government shutdown and health care cuts. Ted also discusses the growing momentum for a bipartisan group of senators' draft bill, the SUSTAIN 340B Act.  He notes that multiple lawmakers expressed support for that effort, including longtime 340B critic Cassidy. Ted also shares insights into the status of the SUSTAIN Act and what might be included in the legislation. Takeaways from 340B Grantees Conference in Atlanta and Industry Conference in NYC Ted and Will discuss their recent trip to Atlanta for the 340B Grantees Fall Conference, where they each moderated panels. Will discusses his panel on state 340B legislative activity and shares providers' concerns that drugmakers could use the 340B program as a bargaining chip in negotiations with the Trump administration on things like direct-to-consumer drug pricing and pharmaceutical tariffs. Ted discusses continued provider concerns with the HRSA's 340B rebate pilot proposal and shares insights on potential 340B negotiations with the Trump administration, which he heard at a separate conference in New York City that had a strong drug industry presence. 340B Report's Rebate Pilot Webinar and Rumblings  Shannon highlights 340B Report's recent subscriber-only webinar on HRSA's 340B rebate pilot proposal, which focused on key implementation concerns and included a lively debate on the rebate proposal's merits. Ted also shares what he is hearing about the status of the rebate model. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs, and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the ongoing federal government shutdown's impact on 340B operations, the latest in the 340B rebate debate and a large drugmaker's move to tighten 340B restrictions on certain hospitals that it believes are not complying with the company's current contract pharmacy policy. Key Topics Covered: Federal Government Shutdown Could Affect 340B Program Operations Shannon explains how the federal government shutdown has led to furloughs at the Health Resources and Services Administration's (HRSA) Office of Pharmacy Affairs—and what that could mean for stakeholders if the shutdown drags on. She also discusses how the shutdown could impact a key upcoming deadline in HRSA's 340B rebate pilot program. Meanwhile, Ted shares his thoughts on politically-charged language about the shutdown that appeared on HRSA's website and the shutdown's real world effects on the HRSA staff and other federal workers. 340B Rebate Pilot Concerns and Upcoming Exclusive 340B Report Webinar Will discusses 340B stakeholders' continued implementation concerns with HRSA's controversial 340B rebate pilot program, including potentially significant financial and administrative burdens for providers. Will and Ted also preview 340B Report's exclusive, subscriber-only webinar on the biggest implementation questions for 340B stakeholders, which will take place on Oct. 15 and include a panel of experts from across the 340B supply chain. Pfizer Tightens 340B Restrictions, Makes Headlines with 'MFN' Move Shannon discusses Pfizer's recent move informing certain 340B hospitals that they could lose their approved one contract pharmacy exemption registered with industry vendor 340B ESP as of Nov. 1. She also explains Pfizer's headline-grabbing move to offer its drugs to Medicaid at a "most favored nation" price and launch a direct-to-consumer prescription drug platform. Shannon discusses why industry observers don't think it will have as significant an impact as it has been heralded by the White House and Pfizer executives. And why some stakeholders view those moves as undermining the drug industry's arguments that 340B drives higher drug prices. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Verity Solutions. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including one drugmaker's removal of medications from the 340B and Medicaid Drug Rebate programs, recent developments in key 340B drug industry lawsuits and dark money groups' efforts to block Michigan's 340B contract pharmacy and reporting bill. Key Topics Covered: Bausch Health Pulls Drugs From 340B, Medicaid Rebate Programs Shannon discusses Bausch Health's recent decision to remove drugs from the 340B and Medicaid rebate programs effective Oct. 1. She notes that while the terminations will affect hundreds of products associated with many of Bausch Health's national drug codes for 340B-eligible drugs, it's unclear whether Bausch will fully remove itself from the 340B program. Attorneys, however, have suggested that drugmakers can't "pick and choose." Ted discusses providers' responses to the forthcoming terminations, including their concerns about the move's financial implications, patient access to medications and whether other drugmakers will follow suit.  Two More Federal Courts Side With States on Contract Pharmacy Protections Will explains the implications of two recent major federal court rulings in favor of state 340B contract pharmacy access laws. The U.S. 5th Circuit Court of Appeals denied AbbVie's bid to block enforcement of Mississippi's law, reaffirming a lower court's decision. Shortly thereafter, a federal district court in Maine denied AbbVie and Novartis' efforts to halt Maine's law, allowing the statute to take effect as scheduled. Michigan's Contract Pharmacy and Reporting Bill Comes Under Fire  Will also discusses a recent Michigan House hearing over a contract pharmacy access bill with reporting requirements for hospitals and manufacturers. Providers strongly supported the bill, while the drug industry and two dark money groups heavily opposed it. The hearing came amid an ongoing feud between the Michigan House speaker and the leader of the state's hospital association. It also came six months after the state Senate easily passed a similar measure. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Plenful. Plenful is the leading AI workflow automation platform transforming how healthcare teams work. Built to empower operators and the patients they serve, Plenful enables healthcare organizations to scale operations with speed, precision, and intelligence. We are very grateful to Plenful for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the 1,000-plus public comments on the Health Resources and Services Administration's (HRSA) 340B rebate pilot proposal, the 340B ACCESS Act's reintroduction in Congress and a new Congressional Budget Office (CBO) report on 340B program growth, which has drawn criticism from provider advocates. Shannon and Will also provide updates on oral arguments in key federal cases that recently went before appeals court judges.   Key Topics Covered: More than 1,000 Stakeholders Weigh-in on HRSA's 340B Rebate Pilot Proposal Will discusses the more than 1,200 stakeholder comments HRSA received over its contentious 340B rebate pilot proposal. He explains why hundreds of 340B providers urged the agency to abandon the rebate pilot altogether and discusses the drug industry's push to expand the pilot to more drugs. Will also breaks down stakeholders' concerns with the one-week turnaround between the comment due date and manufacturers' deadline to submit rebate proposals. CBO Report and ACCESS Act Reintroduction Take Center Stage on Capitol Hill Shannon breaks down the latest version of the 340B ACCESS Act, a controversial 340B overhaul bill which two key House GOP lawmakers reintroduced on Sept. 10. She discusses how the National Association of Community Health Centers has backed off from supporting the measure, which contains many of the provisions included in the May 2024 original version that providers advocates have vocally opposed. Shannon notes that the bill's reintroduction came one day after the nonpartisan CBO released a report on 340B program growth. Ted highlights provider advocates' criticisms of the report and why they believe it misses the mark. Appeals Courts Hear Arguments in Key 340B-Related Cases Will breaks down a trio of oral arguments that recently took place in federal appeals courts over drug industry challenges to state 340B contract pharmacy access laws. The hearings centered on whether the 340B statute's silence on drug delivery allows states to pass contract pharmacy access measures, and the judges asked tough questions of all parties. Shannon provides an update on recent oral arguments in a 5th Circuit Court of Appeals case surrounding a Centers for Medicare and Medicaid Services rule which could affect some hospitals' 340B program eligibility. A group of Texas hospitals have challenged the rule. A Texas federal District Court in 2024 declared it "unlawful" and halted its enforcement. HHS appealed the decision. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by CompassRx, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial. Listen to our newest podcast 340B Leaders Upfront We encourage you to check out 340B Report's new business area podcast, 340B Leaders Upfront, formerly 340B 360°, hosted by Anna Mangum. In the latest episode, Anna interviews two of the leaders of Plenful, an AI service provider company that is providing very cost-effective and highly beneficial services for the 340B provider community.

In this episode, Ted Slafsky, publisher and CEO of 340B Report, and Will Newton, associate editor and senior writer at 340B Report, break down the latest in 340B news, including concerns over the Health Resources and Services Administration's (HRSA) controversial 340B rebate pilot program and a new hospital Medicare reclassification trend that is alarming some rural health advocates. Next, they're joined by Colleen Meiman, a senior policy advisor to state primary care associations, to discuss the incredible life and legacy of Sue Veer, a nationally recognized 340B advocate and educator who passed away last week. Key Topics Covered: HRSA Posts Rebate FAQ, Federal Court Extends Rebate Appeal Deadlines Will discusses HRSA's recently published FAQ that clarifies parts of its contentious 340B rebate pilot program. Then, he explains why a major hospital trade group is urging the agency to abandon the rebate pilot altogether. Will also shares recent updates in the drug industry's litigation challenging HRSA's authority to pre-approve rebates. Rural Health Advocates Alarmed by Hospital Reclassification Trend Will discusses an emerging trend in which some large urban hospitals are reclassifying as rural under the Medicare program. This gives them access to benefits designed for rural providers, including higher Medicare payments and a lower 340B eligibility threshold. Will explains why some rural health advocates are concerned this could deplete rural resources and bring negative scrutiny to the 340B program. Ted also discusses the myriad financial challenges hospitals are facing, including recently enacted steep Medicaid cuts that could threaten 340B eligibility for many.  A Tribute to the Life and Legacy of 340B Champion Sue Veer Special guest Colleen Meiman joins the team to mourn the loss of the late Sue Veer and honor her incredible legacy as a nationally respected 340B program advocate and educator. Colleen shares the incredibly powerful story of why Sue began her career in health care, as well as her close personal relationship with Sue. Next, Ted and Colleen discuss Sue's omnipresence in the 340B space, including her various roles with national provider organizations and reputation as a "straight shooter" respected by all sides of the 340B debate., Colleen also shares a few fun stories about Sue unbeknownst to many. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs, and effective 340B program administration. Visit RxParadigm to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial. Listen to our newest podcast 340B Leaders Upfront We encourage you to check out 340B Report's new business area podcast, 340B Leaders Upfront, formerly 340B 360°, hosted by Anna Mangum. In the latest episode, Anna interviews two of the leaders of Plenful, an AI service provider company that is providing very cost-effective and highly beneficial services for the 340B provider community.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including updates to the comment deadline on the Health Resources and Services Administration's (HRSA) 340B rebate guidance—and why 340B stakeholders say the agency's timeline is not long enough. They also reflect on the implications of a major ruling in an antitrust lawsuit that two health centers filed against drug manufacturers, which were among the first companies to impose 340B contract pharmacy restrictions. The team also discusses new 340B enrollment requirements for sexually transmitted disease (STD) clinics. And Will breaks down a new 340B Report analysis that raises questions about the controversial alliance between the National Association of Community Health Centers (NACHC) and Pharmaceutical Research and Manufacturers of America (PhRMA). Key Topics Covered: HRSA Extends Rebate Pilot Comment Period and HHS Touts Model Shannon offers a recap on HRSA's proposed 340B rebate pilot program, including which drugs would qualify and when manufacturers can deny claims. She discusses a legal filing in which the Health and Human Services (HHS) Department touts its rebate model pilot plan, and she highlights HRSA's recent deadline extension for public comments on the proposal. Ted notes 340B providers' concerns with the rebate model, and why they're asking the agency to extend its consideration timeline for such proposals. Antitrust Case Ruling Sets Stage for Future Litigation Shannon highlights a recent federal appeals court ruling that 340B provider attorneys argue could open the door for future 340B-related lawsuits against drug manufacturers. The U.S. 2nd Circuit Court of Appeals overturned a lower court decision, unanimously ruling that an antitrust class action lawsuit can continue in a lower court. Two community health centers allege in the lawsuit that four major drugmakers illegally colluded to deny 340B pricing on insulin and other diabetes medicines through contract pharmacy restrictions. Ted discusses the legal background surrounding the case and its potential importance. STD Clinic Lawsuits and New Eligibility Requirements Will breaks down multiple lawsuits related to the 340B eligibility of a Nevada-based STD clinic, including multiple sites that HRSA terminated and later reinstated. Shannon notes that a new HRSA proposal would require STD clinics and other 340B covered entities to submit new or more complete information to enroll in or be re-certified in the 340B program. The proposal came just weeks after Office of Pharmacy Affairs (OPA) Director Chantelle Britton hinted at changes affecting STD clinics. Analysis Raises Questions about ASAP 340B Alliance Will discusses his recent analysis of the 340B reform alliance, called ASAP 340B, between the NACHC and PhRMA. Since the two groups formed their unlikely alliance in March 2023, the number of PhRMA member companies that have placed 340B restrictions on health centers has more than doubled—raising questions over how much the alliance has actually benefited NACHC members. Will also breaks down how NACHC's public posture on the alliance has appeared to shift, even as ASAP 340B continues its advocacy efforts and NACHC continues to be listed as one of its founding members. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by VytlOne, the only independent provider of integrated pharmacy solutions. VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. Visit VytlOne to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including the Health Resources and Services Administration's (HRSA) highly anticipated release of proposed 340B rebate guidance—and the significant concerns it garnered from 340B stakeholders. They also reflect on the 340B Coalition's recent summer conference and Capitol Hill lobbying efforts. Key Topics Covered: HRSA Releases 340B Rebate Model Guidance Will discusses the details of HRSA's proposed 340B rebate pilot program, including which drugs would qualify and when manufacturers would be able to deny claims. Though HRSA's proposed 340B rebate pilot, which stakeholders will have 30 days to comment on, is narrower in scope than what had been proposed by various drug makers, it still would mark a dramatic shift to a program that has operated using an upfront discount since its inception more than 30 years ago.  Stakeholders Raise Concerns on Proposed 340B Rebate Pilot Proposal Shannon breaks down how key 340B stakeholders initially responded to HRSA's rebate guidance, including concerns raised by both providers and the drug industry. She notes that hospital groups quickly expressed their opposition to efforts to implement a 340B rebate model, arguing it marks a major departure from how the program's been run and could hurt their financial ability to provide services to low-income patients. Health center groups have not yet weighed in with 340B Report. The drug industry, meanwhile, contends that HRSA's proposal doesn't go far enough and is needed to address what they say are continued challenges in addressing duplicate discounts, Shannon adds.  Key Takeaways from the 340B Coalition's Summer Conference Shannon recaps the 340B Coalition's recent summer conference in National Harbor, Md., including keynote speeches from 340B Health leaders and HRSA's Office of Pharmacy Affairs Director Chantelle Britton. Shannon notes that 340B reform and PBM reform efforts are likely to remain hot topics in Washington, D.C., despite the post-reconciliation budget lull on Capitol Hill. Will discusses covering the fourth annual "Defend 340B" march on Capitol Hill, which took place after the conference and was unaffiliated with the 340B Coalition. He also discusses competing lobbying efforts from two trade groups that took place that week. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This week's episode is sponsored by Pillr Health, a company known for its 340B solutions that emphasize transparency, integrity, and ease of use for covered entities. Visit Pillr Health to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Episode 20: Reconciliation Bill's 340B Impact, CMS' Big 340B Proposals and Rebate Update In this episode, 340B Report Publisher & CEO Ted Slafsky and 340B Report Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest 340B news, including key developments in Washington D.C., a federal 340B rebate court case and the ongoing lobbying effort of the White House's Office of Management and Budget over a potential rebate model. Ted closes the episode with a touching tribute to his late mentor David Gergen. Key Topics Covered: Reconciliation Bill Becomes Law, Key Congressional Subpanel Updates Leaders  Shannon and Will discuss the recent enactment of the GOP-backed reconciliation bill, known as the "Big Beautiful Bill," including what its massive health spending cuts over the next decade could mean for 340B providers. Shannon highlights how 340B-related provisions stripped from the wide-ranging spending legislation have been reintroduced as part of a large bipartisan standalone bill focused on the Pharmacy Benefit Manager industry. And Ted discusses recent leadership changes on the House Energy and Commerce Health Subcommittee following U.S. Rep. Buddy Carter's (R-Ga.) decision to step down as chair as he runs for U.S. Senate. CMS Proposes Rules With Major 340B Implications Shannon and Will break down how two new Centers for Medicare and Medicaid Services (CMS) proposed rules would affect the 340B program. Shannon offers an overview of CMS' Outpatient Prospective Payment System (OPPS) draft rule and its significant implications for the 340B community. It contains controversial provisions to accelerate hospital outpatient payment cuts to offset previous 340B hospital lump sum repayments, as well as plans to survey hospital acquisition costs for certain outpatient medications. Next, Will discusses CMS' proposal to establish, for the first time, claims-based approaches to identifying 340B claims billed to Medicare Part D. 340B Rebate Model Debates Heats Up Will discusses the latest in drug industry efforts to implement controversial 340B rebate models. Four drugmakers are currently appealing a pair of lower courts' rebate rulings, while dozens of program stakeholders—including drugmakers, providers and technology vendors—are meeting with federal officials in an effort to sway highly anticipated federal 340B rebate guidance. Tribute to David Gergen Ted offers a touching tribute to David Gergen, his first mentor and boss out of college. Gergen was a senior adviser to four U.S. presidents and a highly influential editor and political commentator. Ted reflects on his inspiring career and shares his thoughts on his mentorship. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Verity Solutions sponsored this week's episode. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including key developments in a federal 340B rebate model court case, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.'s latest remarks on the Trump administration's efforts to lower prescription drug prices and two New England states' embrace of new 340B contract pharmacy access and provider reporting laws. Key Topics Covered: Appeals Court Expedites Schedule in 340B Rebate Case  Will recaps recent developments in the drug industry efforts to convert upfront 340B discounts to post-purchase rebate models. After a federal district court in Washington, D.C. ruled that drugmakers cannot implement 340B rebates without HHS approval, multiple drug companies appealed. Meanwhile, hospital trade group 340B Health filed a cross-appeal arguing that the court should have ruled that the 340B statute "categorically prohibits" rebates. While those appeals play out, stakeholders are also meeting with HHS about the agency's 340B rebate guidance, which is not yet public pending regulatory review. RFK Jr. Touts Administration's Drug Pricing Plans, Key Lawmaker Talks 340B Shannon breaks down Kennedy's recent appearance before the House Energy and Commerce Committee's Health Subcommittee to testify on President Donald Trump's budget proposal. While the HHS secretary did touch on the budget's controversial plan to shift 340B oversight within the agency, Shannon notes that he touted the administration's efforts to lower prescription drug prices through recent executive actions and endorsed pharmacy benefit manager reform efforts. She discusses how U.S. Rep. Diana Harshbarger (R-Tenn.) briefly floated the potential for renegotiated "340B contracts" during her exchange with Kennedy—comments which some 340B advocates criticized as a misunderstanding of the 340B program's structure. Will provides an update on another drug pricing executive order. New England States Embrace Contract Pharmacy Access, Provider Reporting Laws  Will provides an update on Maine's recent enactment of a contract pharmacy access and reporting law. Shannon notes that Rhode Island is on the cusp of signing similar legislation into law. With 20 states now having enacted contract pharmacy protections, Will breaks down the latest trends in state 340B legislation. He discusses the increasing number of states that have passed bills that contain both contract pharmacy access and reporting provisions in 2025.  Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. CompassRx sponsored this week's episode. CompassRx is the premier AI-services platform built exclusively for 340B covered entities. We are very grateful to CompassRx for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Episode 18: Impending Rebate Guidance, Possible 340B Move from HRSA to CMS & Oklahoma's Veto Override In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the U.S. Department of Health and Human Services' (HHS) submission of 340B rebate guidance for regulatory review, a proposal to shift 340B oversight to the Centers for Medicare & Medicaid Services (CMS), U.S. Sen. Bill Cassidy's (R-La.) latest comments on 340B and Oklahoma's 340B contract pharmacy legislation veto override. In This Episode:  Rebate Updates  Will provides an update on the latest surrounding drugmakers' attempts to convert upfront 340B discounts to a post-purchase rebate model. He discusses HHS' June 1 submission of proposed 340B rebate guidance to the Office of Management and Budget, which will remain confidential throughout the review. Meanwhile, drugmakers Novartis and Bristol Myers Squibb filed an emergency motion to expedite their legal challenge to a ruling that affirms the government's authority to pre-approve 340B rebate models—citing looming compliance deadlines under the Inflation Reduction Act. A Proposed Shift to CMS and Other Federal Happenings  Shannon and Ted break down President Donald Trump's full HHS budget request that calls for moving the Health Resources and Services Administration's (HRSA) Office of Pharmacy Affairs (OPA), which oversees the 340B program, to CMS. They discuss the differences between the formal proposal and a version included in a leaked document, as well as 340B stakeholders' reaction to such a move. Shannon and Ted also discuss key federal players on 340B, including Cassidy's latest remarks on potential congressional reform plans and the return to the private sector of Katie Miller, a Trump adviser tied to a dark-money group running anti-340B ads in various states. The State of the States  Will recaps Oklahoma's path to enacting a contract pharmacy access law, which included a gubernatorial veto and legislative override. He and Bella discuss the latest state-level action on 340B bills, as well as how drugmakers have responded to Tennessee's unique contract pharmacy access law. Subscribe & Stay Updated: How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce sponsored this week's episode. PharmaForce is the only Third Party Administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.  

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editor and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including a major federal court ruling on drugmaker 340B rebate models, Health and Human Services (HHS) Secretary Robert F Kennedy Jr.'s first public comments on the 340B program and the Oklahoma governor's decision to veto a widely supported contract pharmacy access bill. Key Topics Covered: Court Upholds HHS' Right to Pre-Approve 340B Rebates Will recaps the latest developments in a key 340B rebate lawsuit, including a recent opinion from the Washington D.C. U.S. District Court that rejected drugmakers' claims that HHS acted unlawfully by requiring pre-approval of their 340B rebate proposals. He dives into the implications of the ruling, which doesn't rule out the possibility of drugmaker rebates in the future, what it means for stakeholders and how key 340B players responded.  RFK Jr. Offers 1st Public Comments on 340B, Trump Issues Drug Pricing EO  Shannon breaks down Kennedy's first public comments on the 340B program, which came during his recent testimony before House and Senate subcommittees. She and Ted discuss how the HHS secretary's comments about the program largely reflect drug industry talking points, as well as the pushback the comments drew from 340B providers. Shannon also offers an update on budget reconciliation talks and discusses President Donald Trump's new "most-favored nation" drug pricing executive order. She and Ted note the challenges the White House could face in advancing efforts to lower drug prices. Oklahoma Governor Vetoes Contract Pharmacy Bill Following Dark-Money Campaign Will provides an update on Oklahoma's efforts to pass contract pharmacy access legislation after Gov. Kevin (R) vetoed a bill, which cleared the legislature with widespread support. Will discusses the role that misleading dark-money ads may have played in the governor's decision, and how GOP lawmakers, who were the lead sponsors of the 340B legislation, are pushing to override that veto. Subscribe & Stay Updated: How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. RxParadigm sponsored this week's episode. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs, and effective 340B program administration. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editor and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including developments in two major 340B lawsuits, new state contract pharmacy access laws with unique twists and developments on health funding negotiations and drug pricing policy talks in Washington, D.C. Key Topics Covered: Courts Hear Arguments in 340B Rebate, Antitrust Lawsuits Will recaps the latest developments in a key 340B rebate lawsuit, including recent oral arguments in which the drug industry argued it doesn't need federal approval to institute rebate models. HHS has told the drug manufacturers that they are not allowed to unilaterally implement a rebate model and a hospital group has intervened to oppose the use of rebates.  The judge grilled attorneys representing both the drug industry and the Department of Health and Human Services (HHS). HHS later committed to issuing guidance on a rebate model—and what conditions, if any, they could be permitted—within the next few weeks. Bella recaps the recent oral arguments in a 340B antitrust case against four major insulin manufacturers. Ted and Bella discuss the significant implications of this case for 340B covered entities, should the appeals court side with the two health centers that have accused drugmakers of colluding on contract pharmacy restrictions. More States Advance Contract Pharmacy Bills Will provides an overview of recent contract pharmacy access bill developments in Oklahoma, Colorado and Hawaii. He notes some of the unique provisions contained in those bills, such as new reporting requirements for providers.   Drug Pricing Talks Loom Large Shannon breaks down the latest developments on Capitol Hill as congressional Republicans work to wrap up wide-ranging spending legislation, which calls for $880 billion in health spending cuts that are largely expected to target Medicaid. The White House has proposed tying Medicaid drug prices to the prices paid in other affluent countries—a policy which has drawn pushback from both the drug industry and provider advocates. Ted recalls a similar initiative President Donald Trump pursued in his first term to tie dozens of Medicare Part B drugs prices to their international equivalents. Shannon also discusses new federal drug pricing legislation and Trump's HHS budget blueprint.   Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   Each episode is brought to you by one of our great Ultra Diamond sponsors. Maxor sponsored this week's episode. From specialty pharmacies to comprehensive pharmacy management, Maxor optimizes the pharmacy experience for patients and partners. We are very grateful to Maxor for its sponsorship.   Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher & CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski to break down the latest developments in the 340B space. The team discusses Senate HELP Committee Chair Bill Cassidy's (R-La.) high-profile report on the 340B program, an executive order sparking concerns among providers, reactions to potential pharmaceutical tariffs and important state 340B bills in Indiana and Tennessee. Key Topics Covered: Senate Report Calls for Congressional 340B Reform Sen. Cassidy unveiled the long-awaited findings of his two-year investigation into the 340B program with a 200-page report that criticized multiple 340B providers and called for significant congressional 340B reform that echoes many drug industry policy asks. Shannon and Ted discuss the implications of the report and stakeholder reactions to it, as well as the latest on a separate bipartisan Senate 340B legislative effort that's expected to be more provider friendly.  Executive Order and Tariffs Spark Concerns Will Newton breaks down President Donald Trump's (R) recent executive order that attempts to revive a controversial rule requiring health centers to pass all 340B savings on insulin and EpiPens directly to certain low-income patients. The order also calls for a survey on hospital acquisition costs—the likely precursor to an attempt to reduce Medicare Part B payments to 340B hospitals. Providers have raised alarm bells over both proposals. Bella discusses the administration's proposed tariffs on pharmaceuticals and why both drugmakers and provider advocates are warning that they could be problematic for the pharmaceutical supply and patients. State 340B Bills in Indiana and Tennessee Will breaks down a 340B hospital reporting bill in Indiana and a contract pharmacy bill in Tennessee that are both likely to soon become law. Tennessee's unique bill grandfathers in existing drugmaker 340B restrictions but requires the "winners-only" contract pharmacy model that's popular among providers.  Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. This week's episode is sponsored by Pillr Health, a company known for its 340B solutions that emphasize transparency, integrity, and ease of use for covered entities. Visit PillrHealth.com to learn more. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.  

In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the latest states to enact contract pharmacy access laws, updates in key lawsuits and new U.S. Department of Health and Human Services (HHS) restructuring efforts. Key Topics Covered: New State Contract Pharmacy Access Laws Will highlights new contract pharmacy access laws enacted in Nebraska and Utah, including when they take effect and how their respective state governors approached the legislation. He also briefly discusses New Mexico's newly enacted contract pharmacy access law, which does not take effect until 2026 and is the only enacted state contract pharmacy protection statute that only applies to health centers. Key Updates in Drug Industry Lawsuits and State Enforcement Action Will also breaks down a Minnesota federal district judge's order to dismiss two drug industry lawsuits challenging that state's contract pharmacy access law. The judge ruled that the drugmakers had no legal standing to sue the state over its contract pharmacy law since Minnesota's law—unlike most other existing state contract pharmacy protection statutes—has no enforcement mechanism. Meanwhile, in Arkansas, a state official recently ordered AstraZeneca to restore access to 340B drugs at all contract pharmacy locations. AstraZeneca had been the only major manufacturer not to comply with Arkansas' first-in-the-nation contract pharmacy access law after a federal appeals court panel unanimously upheld the statute in March 2024. A New CMS Leader and HHS Restructuring Shannon and Bella provide an update on 340B-related activity at the federal level. Bella discusses the U.S. Senate's recent confirmation of Mehmet Oz as the new administrator of the Centers for Medicare and Medicaid Services (CMS). Shannon highlights the recent restructuring at HHS and rumored efforts to move the 340B program into CMS.  Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors. Verity Solutions sponsored this week's episode. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, the Inside 340B Report team dives into a flurry of activity at the state and federal levels. Publisher and CEO Ted Slafsky and Associate Editor/Senior Writers Shannon Young and Will Newton break down the unprecedented wave of state-level 340B contract pharmacy access and provider reporting bills, explore key federal movements, including the latest on the bipartisan U.S. Senate working group behind the SUSTAIN 340B Act, and provide an update on 340B rebate litigation. Key Topics Covered: State Legislative Activity Heats Up The team discusses the recent surge in legislative action on state 340B bills as more than 25 states have introduced contract pharmacy access bills in 2025. South Dakota and Utah recently enacted contract pharmacy laws in 2025, joining eight other states that passed similar bills in previous years, while bills in New Mexico and North Dakota are awaiting action from their state governors. Will also highlights several state bills that would place a range of reporting requirements—and in some cases significant restrictions—on 340B providers. Federal Legislative Developments and Bipartisan Efforts Shannon provides updates on the latest developments on the 340B front in Washington, D.C., including the new members of the bipartisan group of six senators working on 340B overhaul legislation known as the SUSTAIN 340B Act. She and Ted also highlight other federal bills that could resurface this session, including the provider-supported 340B PATIENTS Act and drug industry-backed 340B ACCESS Act. The team also provides an update on Mehmet Oz's nomination to lead the Centers for Medicare & Medicaid Services (CMS), focusing on a new Washington Post story that highlighted 340B Report's previous reporting on his undisclosed ties to ZorroRx, a health benefits company that partners with 340B hospitals. Despite facing new ethics concerns, Oz has not drawn much scrutiny from lawmakers during the confirmation process over his 340B ties or stance on the program—a shift from previous nominees. Rebate Litigation Developments Will explains recent developments in ongoing lawsuits that pharmaceutical giants, like Johnson & Johnson and Eli Lilly, have filed against the federal Health Resources and Services Administration (HRSA) in their attempts to unilaterally impose 340B rebate models. Notably, in a series of recent court filings, President Donald Trump's (R) administration has chosen to continue to defend HRSA's long-standing position that drugmakers cannot implement 340B rebate models without explicit agency approval, offering some relief to the 340B provider community. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by CompassRx, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize your 340B savings and operational efficiency. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode of Inside 340B Report, Ted Slafsky, Will Newton and Bella Czajkowski explore the latest developments in the 340B world at both the state and federal levels. They cover the progress of contract pharmacy access bills across the country—including a breaking news development—plus dark money efforts to oppose the legislation. They also break down key updates in drugmaker rebate lawsuits and provide an update on federal budget talks including major cuts expected for the Medicaid program and where we may be headed on the 340B program. Key Topics Covered: Contract Pharmacy Bills Progress, Despite Resistance                                                                           Will summarizes recent key votes on state contract pharmacy access bills and provider reporting legislation. He also breaks the news that South Dakota became the first state in 2025 to enact contract pharmacy protections after hearing from the governor's office mid-recording. Meanwhile, Bella highlights the tactics of dark money efforts to oppose contract pharmacy legislation through misleading ads, noting that many of the efforts appear to be backfiring. Drugmaker Rebate Litigation Heats Up                                                                                                        The team discusses five drugmakers' ongoing legal efforts to implement 340B rebate models without approval from the Health Resources and Services Administration. Bella and Will explain the significance of the recent decision allowing the hospital advocacy group 340B Health and two of its member hospitals to intervene in four of those cases, all while other major provider advocacy groups have filed amicus briefs opposing the rebate models. Budget Talks and the Looming Federal Shutdown                                                                                     With crucial budget negotiations unfolding in Congress, Ted breaks down the potential impact of proposed healthcare funding cuts totaling $880 billion over the next decade. These cuts could have significant effects on Medicaid, directly affecting 340B providers and the patients they serve. Ted notes that 340B stakeholders should keep a close eye on Capitol Hill as budget battles continue, especially given the possibility of a government shutdown.  He also talks about the leaders of key committees with jurisdiction over the 340B program and what that could mean for 340B stakeholders. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce is the only third-party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We're grateful to PharmaForce for making this episode possible. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode of Inside 340B Report, Ted Slafsky, Shannon Young, Will Newton and Bella Czajkowski discuss what may be a record-breaking year for state contract pharmacy access legislation with more than 20 states having already introduced such bills in 2025. On the federal front, the U.S. House's budget blueprint targeting $880 billion in health spending cuts over the next decade has raised alarm bells among providers over potential significant Medicaid reductions. Finally, Ted and Shannon share takeaways from last week's 340B Coalition Winter Conference in San Diego, where these topics and others were center stage. Key Topics Covered: State Legislative Surge and Legal Developments As of Feb. 28, at least 21 states had introduced new contract pharmacy access bills. Ted and Bella discuss the significance of major states like California, Texas and New York joining the fray with their own 340B access bill proposals. Will also discusses several of the states that have advanced their contract pharmacy bills, before joining Ted and Bella to provide updates on critical legal battles unfolding in states that have already passed contract pharmacy access laws, including Missouri, Kansas and West Virginia.  Budget Blueprint and Medicaid Concerns In Washington, D.C., the House recently passed a budget framework that calls for $880 billion in health spending cuts over the next decade. Shannon discusses the potential implications for Medicaid funding and how these budgetary moves might indirectly impact the 340B program.  340B Coalition Conference Insights Shannon and Ted break down the key issues that dominated the 340B Coalition's recent Winter Conference, including the status of three key federal 340B bills, new scrutiny U.S. Sen. Bill Cassidy (R-La.) could bring to the 340B program as the new HELP Committee chairman and how a Washington D.C. dark-money group's campaign targeting 340B access bills could play out at statehouses. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Pillr Health sponsored this week's episode. Pillr Health is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations. It focuses on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program and beyond. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Episode 10: State-Level 340B Bills Gain Momentum, Dark Money Ads Intensify and D.C. Developments In this episode of Inside 340B Report, Ted, Shannon, Will and Bella break down the latest developments shaping the 340B landscape. The team discusses the latest state contract pharmacy bill developments and a dark-money group's lobbying against them. They also touch on new GOP congressional budget proposals, new leadership at HHS and HRSA and key U.S. Senators' remarks on 340B's future. Key Topics Covered:  State Contract Pharmacy Access and Provider Reporting Bills              With the 2025 legislative sessions underway, at least 16 states have introduced bills aimed at preventing drug manufacturers from restricting covered entities' access to 340B drugs through contract pharmacies. Meanwhile, several states have introduced legislation that would require 340B providers to publicly report financial data on their 340B savings, and how they reinvest them into patient care. While some bills, like one in Colorado, are more narrow in scope, others, such as those in Indiana and Vermont, impose extensive reporting requirements that many providers believe are overly burdensome and lack important context. Dark Money Campaign Targeting Contract Pharmacy Access Bills Building America's Future, a dark money group that does not disclose its donors, has launched a new misleading ad campaign in four GOP-controlled states with pending contract pharmacy access bills that falsely claim 340B funds subsidize gender transitions for minors. Although the ads urge conservative lawmakers to reject the legislation, lawmakers in Kentucky and Nebraska advanced their bills.  Federal Developments House and Senate Republicans have unveiled budget proposals that call for deep healthcare spending reductions, signaling potential major Medicaid cuts. The Senate voted to confirm Robert F. Kennedy Jr.'s nomination to lead HHS despite vocal pushback from Democrats. And the Health Resources and Services Administration swore in a new administrator.  Two key U.S. Senators gave remarks on 340B at a D.C. conference hosted by the National Association of Community Health Centers. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. This year, each episode will be brought to you by one of our Ultra Diamond sponsors. RxParadigm sponsored this week's episode. RxParadigm is a technology solutions provider committed to supporting initiatives that advance the 340B program. We are very grateful to RxParadigm for its sponsorship. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode of Inside 340B Report, Associate Editors Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest developments in the 340B program in statehouses and Washington, D.C. The team covers the intensifying fight over state-level 340B legislation and the reemergence of a controversial dark-money ad campaign, Health and Human Services Secretary nominee Robert F. Kennedy Jr.'s contentious Senate confirmation hearings and the recent turmoil surrounding a now-rescinded federal funding freeze. Key Topics Covered:  State-Level 340B Legislative Surge At least 11 states have already introduced 340B contract pharmacy protection bills in early 2025 after a record-setting level of state 340B legislative activity in 2024. With both advocates and opponents more prepared than ever, the legislative battle is heating up. Meanwhile, a shadowy group, Building America's Future, is once again launching misleading ad campaigns against state 340B contract pharmacy access bills that attempt to link that legislation to illegal immigration and other hot-button political and social issues. Senate Confirmations – RFK Jr.'s 340B Stance Still Unclear, Mehmet Oz Tied to Company That Focuses on 340B Despite six-plus hours of testimony and questions from Senate lawmakers, Robert F. Kennedy Jr.'s stance on 340B is still unclear. The HHS secretary nominee's confirmation hearings did not touch on the drug pricing program, with lawmakers instead focusing primarily on the high-profile vaccine skeptic's controversial statements about vaccines and his grasp of Medicare and Medicaid. Meanwhile, a 340B Report exclusive reveals that Mehmet Oz, President Donald Trump's nominee to lead the Centers for Medicare and Medicaid Services, has recent ties to a company that works with 340B hospitals to utilize the 340B program. With his son continuing to play a senior role in the business, Oz's confirmation process could enable senators to learn more about his position on the 340B program.    Federal Funding Freeze Sparks Chaos – Then Gets Reversed A Trump administration memo that temporarily froze trillions in federal funds sent shockwaves through the healthcare sector, including 340B providers and community health centers. The freeze was quickly blocked by a judge and later rescinded, but concerns linger over future budget cuts. Republicans on Capitol Hill are also mulling potential Medicaid cuts to help cover the cost of Trump administration priorities, as well as restrictions on what 340B providers could charge employer-sponsored health plans for discounted drugs. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. This year, each episode will be brought to you by one of our Ultra Diamond sponsors. Maxor sponsored this week's episode. From specialty pharmacies to comprehensive pharmacy management, Maxor optimizes the pharmacy experience for patients and partners. We are very grateful to Maxor for its sponsorship. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this new episode, Ted Slafsky catches up with Will Newton and Bella Czajkowski to analyze the latest 340B developments at both the federal and state levels, plus new scrutiny over the program and some of its stakeholders. With the 119th Congress underway, Ted explains what House and Senate committees and lawmakers 340B stakeholders should keep an eye on with narrow Republican control in both chambers. They also discuss the surge in new state-level 340B legislation, detail mixed reactions to a recent New York Times investigation on the 340B prime vendor Apexus, and recap a high-profile lawsuit and HRSA action against a Nevada STD clinic. Key Topics Covered:  Congressional Landscape and Leadership Changes Narrow Republican majorities in the House and Senate set the stage for new GOP-backed scrutiny of the 340B program. Ted walks through the key committees and players that will determine 340B's future.  With 340B expected to be a major priority in the 119th Congress, covered entities and manufacturers are closely watching Capitol Hill and adjusting their policy strategies.  State-Level 340B Legislation Lawmakers in at least five states have reintroduced bills that would prohibit drug manufacturers from restricting 340B access to contract pharmacies. Meanwhile, a new bill in Missouri would place significant limitations on how providers use their 340B savings, drawing pushback from the provider community. The early state activity in 2025 comes after a record-setting year for state contract pharmacy protection legislation in 2024. High-Profile Paper Investigates 340B Prime Vendor After the New York Times published a lengthy investigation alleging that the 340B prime vendor, Apexus, profited by driving 340B program expansion, critics of the program were quick to call for major reforms. However, multiple 340B providers criticized the piece for mischaracterizing the 340B program and defended Apexus' role in ensuring 340B compliance and integrity. The longtime Apexus leader said the Times's investigation contained inaccuracies and "misleading narratives." Scrutiny Over Nevada STD Clinic and its Potential Broader Impact The Health Resources and Services Administration (HRSA) recently terminated the 340B eligibility of 20 sites affiliated with the Nevada-based STD clinic Sagebrush Health, alleging they violated program eligibility standards. HRSA's move came shortly after multiple drugmakers sued the agency for allegedly allowing Sagebrush to register many of those sites in violation of the 340B statute. Sagebrush has strongly denied those allegations and vowed to fight HRSA's action, and some providers worry that the lawsuit could have far-reaching consequences for all STD clinics enrolled in the 340B program. How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. This year, each episode will be brought to you by one of our Ultra Diamond sponsors. Verity Solutions sponsored this week's episode. Verity's innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity for its sponsorship. Subscribe to 340B Report with a Special Discount Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this final episode of the year, Ted Slafsky, Will Newton and Shannon Young unpack the most significant developments in the 340B program in both recent weeks and 2024. From the escalating legal battles over proposed 340B rebate models and pivotal state legislation to key court decisions and congressional activity, the team provides in-depth analysis of the year's top stories. They also share insights into what these shifts could mean for stakeholders and preview the issues expected to dominate the 340B landscape in 2025. Key Topics Covered:  The Rebate Model Debate Will provides an update on the escalating legal battle over rebate models, including HRSA's recent enforcement threats against Sanofi, and how they compare to Johnson & Johnson, Eli Lilly, and Bristol-Myers Squibb's rebate proposals.  State-Level Action on 340B Contract Pharmacy Laws Will discusses the latest state-based actions on 340B, including Michigan's bid to pass a contract pharmacy access law, the Kansas attorney general's unexpected legal interpretation of that state's contract pharmacy law and a recent federal district court ruling in West Virginia in favor of the drug industry. That West Virginia ruling sharply contrasted with earlier court decisions favoring state laws in Arkansas, Louisiana and Mississippi. Federal Legislative Changes and Key Lawmakers Shannon provides an update on the incoming 119th Congress. She discusses how leadership shifts on the House Energy and Commerce Committee could influence 340B policy in 2025 and beyond. Ted discusses the House lawmakers who could play key roles in 340B policymaking. They include members who have raised serious concerns with the program such as Reps. Buddy Carter (R-GA) and Harshbarger (R-TN) and strong program supporters, like Reps. Dusty Johnson (R-SD), Doris Matsui (D-CA) and Diana DeGette (D-CO). Top Stories of 2024 The episode wraps with a look back at the most-read 340B stories of the year. From the rebate model saga and states' 340B legislative efforts, to the Inflation Reduction Act's impact on 340B, the team reflects on the growing importance of state-level action and anticipates continued court battles and policy debates in 2025. What's Next for Inside 340B Report In future episodes, the team will provide an inside look at the issues impacting the stakeholders in the 340B program. Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important.  Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions. Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com. Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

Join Ted Slafsky, Shannon Young, Will Newton and Bella Czajkowski for another episode of Inside 340B Report. This week, the team unpacks the latest developments shaping the 340B landscape, from the announcement by drug manufacturers of new rebate models they hope to implement to expanding contract pharmacy restrictions. They also discuss how the incoming Republican-controlled Congress and White House could impact the 340B program. Key Topics Covered 340B Rebate Models and Legal Battles Will dives into the uptick in 340B rebate proposals from Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb and Sanofi. Learn how these proposals, if implemented, could shift regulatory authority away from the government and into the hands of manufacturers, and potentially decrease provider savings. Contract Pharmacy Restrictions on Health Centers Bella sheds light on the growing number of drug manufacturers that have expanded contract pharmacy restrictions beyond hospitals to community health centers. She shares provider accounts of how these restrictions are straining services, leading to layoffs and impacting rural and underserved communities. Bella also discusses a new tool available only for 340B Report subscribers that tracks each manufacturer's restrictions. Post-Election Landscape for 340B Shannon shares insights from a recent 340B Report subscriber-only webinar on the 2024 elections and their implications for 340B policy. With a new Republican trifecta in Washington—and Republican President-elect Donald Trump filling out his healthcare cabinet— she and the team analyze how the leadership changes could affect federal policymaking. And with a historically narrow GOP margin in the U.S. House, it could be a boon for bipartisan-backed 340B bills, like the SUSTAIN 340B Act. What's Next for Inside 340B Report In future episodes, the team will provide an inside look at the issues impacting the stakeholders in the 340B drug discount program. Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important.  Stay tuned for more episodes biweekly! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions. Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com. Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.  

Ted Slafsky joins Shannon Young, Will Newton and Bella Czajkowski to analyze the 2024 election's potential impact on the 340B landscape, including how President-elect Donald Trump's return to the White House and the new GOP-controlled Congress could approach the drug pricing program.The team also discusses Johnson & Johnson's (J&J) recent lawsuit against the Health Resources and Services Administration (HRSA), marking a pivotal moment in the ongoing 340B rebate model debate. Key Topics Covered Election Results and 340B Policy Implications The team unpacks the election results, including Trump's decisive win and the new GOP leadership in Congress. They discuss how this shift could influence 340B policy, noting that the previous Trump administration posed several challenges to 340B providers. Will and Shannon share insights on expected policy changes and what roles key Senate and House lawmakers could play when it comes to crafting future 340B-related legislation. J&J's Legal Battle Over the Rebate Model Will breaks down J&J's lawsuit against HRSA over its  proposed 340B rebate model, explaining how it could potentially reshape the 340B program. Despite bipartisan resistance to rebates, J&J may be betting on a more drug industry-friendly new administration that could lead to a shift in HRSA's longstanding position on upfront discounts. Spotlight on Key Players With Senate Republicans selecting U.S. Sen. John Thune (R-S.D.) as the next majority leader, the team examines how he could help elevate 340B policy in the upper chamber and potentially moderate critiques from vocal 340B opponents like U.S. Sen. Bill Cassidy (R-La.), who will take over the Senate Health, Education, Labor and Pensions Committee. Cassidy is expected to bring more aggressive oversight to the 340B program.  Thune's historic support of 340B could act as a counterbalance. What's Next for Inside 340B Report In future episodes, the team will provide an inside look at the issues impacting the stakeholders in the 340B drug discount program. Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important.  Stay tuned for more episodes biweekly! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions. Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com.  

Will Newton hosted this week's episode, leading a discussion with Shannon Young and Bella Czajkowski. Ted Slafsky was away for this edition, but we look forward to welcoming him back next time. In this new episode, the editorial team explores emerging trends in drugmaker contract pharmacy restrictions, legal developments around 340B eligibility calculations and manufacturer audits of covered entities, and how the upcoming congressional and presidential elections could shift the program's future.  Key Topics Covered Emerging Trends in Contract Pharmacy Restrictions Bella overviews recent drugmaker moves to restrict contract pharmacy access beyond hospitals, sharing a recent report of an Ohio health center that had to lay off staff due to revenue loss from such restrictions. Shannon and Will add insights into how these moves by manufacturers impact covered entities, increasingly affecting access for both hospitals and health centers. Key Developments in 340B Lawsuits The team updates listeners on pivotal court cases that could reshape the program. Shannon covers a ruling favoring Texas hospitals in a suit against HHS, centered on the Inpatient Prospective Payment Services rule, which affects certain hospitals' 340B eligibility. Will adds an overview of lawsuits challenging the Health Resources and Services Administration's (HRSA) approvals for Johnson & Johnson's audits of 340B-covered entities, examining allegations that HRSA may have acted unlawfully. The team discusses the broader implications these cases may have on 340B. Potential Impact of Upcoming Elections As election season heats up, the team examines how winners of the 2024 congressional and presidential races could influence 340B policy. They also overview how state-level races will play a role in legislative priorities over the coming term.  What's Next for Inside 340B Report In future episodes, the team will provide an inside look at the issues impacting the stakeholders in the 340B drug discount program. Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important.  Stay tuned for more episodes biweekly! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions. Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com. Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.  

Episode 3: The 340B Rebate Saga: Fallout and Potential Litigation Shannon Young, Will Newton and Bella Czajkowski, explore the biggest developments in the 340B program, focusing on the latest surrounding Johnson & Johnson's (J&J) rebate proposal, including the potential for litigation. They also recap key discussions from a recent healthcare summit in New York City and offer a preview of what they'll be keeping their eyes on ahead of the upcoming November elections. Key Topics Covered 340B Report Correspondent Bella Czajkowski attended the Association for Value-Based Cancer Care Summit in New York, where she heard from influential voices on the future of healthcare policy, including 340B. Among the most notable speakers was Joe Grogan, a former Trump administration official, who called for reform to the 340B program—potentially including a rebate model instead of upfront discounts. He cited concerns with possible diversion and the risk of duplicate discounts. Grogan also forecasted the future of the Inflation Reduction Act (IRA). The team discusses 340B stakeholders' reactions to J&J's proposed 340B rebate model. The drugmaker has abandoned course following HRSA pushback, but as Bella points out, some stakeholders say litigation may be on the horizon. Shannon highlights a recent op-ed from Maureen Testoni, in which the president and CEO of 340B Health warned covered entities to stay alert on the issue. And she notes how drug industry trade groups have continued to push for a rebate system. Will discusses how the IRA's Medicare drug price negotiations could interact with the 340B program, including potentially reducing 340B savings. He emphasizes how inaction from federal regulators on the overlap between 340B and the IRA has created looming uncertainty for providers and manufacturers navigating the two drug pricing programs. As the election season heats up, Shannon, Will and Bella preview what they expect to see when it comes to 340B-related lobbying efforts, and how the program could become a household name as it draws more attention at the state and national levels.  What's Next for Inside 340B Report In future episodes, the team will provide an inside look at the topics and issues impacting the stakeholders in the 340B drug discount program. Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important.  Stay tuned for more episodes biweekly! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions. Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com. Special discount for YouTube and podcast listeners who are first-time subscribers. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code: PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In episode 2, host Ted Slafsky, along with Will Newton and Bella Czajkowski, recap major news impacting the 340B program, including the future of manufacturer efforts to convert 340B to a rebate, Sen. Bill Cassidy's latest inquiry into two drugmakers, pushback from bipartisan House members to the rebate proposal federal 340B legislation and key state developments.  Key Topics Covered Johnson & Johnson recently dropped its 340B rebate proposal amid strong enforcement threats from the federal government, but manufacturer efforts to convert the 340B program to a rebate model are likely to continue. The crew discusses the implications of the government's response to J&J's proposal and what it means for other manufacturer efforts to pursue 340B rebate models. They also explain how 340B rebates may arise in response to an inquiry from influential Republican Sen. Bill Cassidy, who has often been critical of 340B program growth.  Key lawmakers with a more favorable view of the 340B program have also been engaged in a flurry of legislative and policy making activity. The crew shares insights into a bipartisan House letter opposing 340B rebates and the status of a Senate bill to restore 340B discounts to contract pharmacies. They also touch on the implications of a children's Medicaid enrollment bill with 340B provisions and two major updates on state-level battles over contract pharmacy access laws.  What's Next for Inside 340B Report In future episodes, the team will provide an inside look at the topics and issues impacting the stakeholders in the 340B drug discount program.  Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important.  Stay tuned for more episodes biweekly! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions. Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com. Special discount for YouTube and podcast listeners.  340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code: PODCAST25.  Not ready to subscribe? Sign up for a 15-day free trial.

Episode 1: Introducing the Inside 340B Report Editorial Team Welcome to the very first episode of the Inside 340B Report podcast! In this debut episode, host Ted Slafsky, publisher and CEO of 340B Report, introduces listeners to the dynamic editorial team behind the show, Shannon Young, Will Newton, and Bella Czajkowski, as they share their backgrounds, experiences, and what drives their passion for the 340B Drug Discount Program. Meet the Team Ted Slafsky kicks off the episode by sharing his extensive background in journalism and advocacy. From his early days at U.S. News and World Report to his longtime  leadership role in 340B advocacy, Ted's journey has been marked by a deep commitment to informing and advocating for crucial health care access issues. His role at 340B Report represents the culmination of years of experience in both journalism and public policy. Shannon Young joins the conversation from the Berkshires, Massachusetts. With a background in state house reporting and stints at Politico and Morning Brew, Shannon brings a wealth of experience in healthcare policy. She discusses her journey from high school newspaper editor to covering complex state and federal healthcare issues, including her personal connection to the pharmacy industry through her father. Will Newton reflects on his path from Fort Worth, Texas, to Washington, DC, where he now serves as an Associate Editor. A Williams College graduate, his prior work in New York City focused on pharmaceutical industry reporting and FDA regulations. Will shares his insights into the complexities of drug pricing and the safety net healthcare system, emphasizing the importance of transparency and understanding in this evolving field. Bella Czajkowski, a Columbia Journalism School graduate and former editor in chief of the Ohio State University newspaper, shares her background from growing up in the Midwest to her recent work on the podcast "An Arm and a Leg," which focuses on healthcare costs. Bella's passion for healthcare policy and investigative reporting shines through as she discusses the intricacies of the 340B program and her excitement about diving into this new role. What's Next for Inside 340B Report In future episodes, the team will provide an inside look at the topics and issues impacting the stakeholders in the 340B drug discount program.  Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important.  Stay tuned for more episodes bimonthly! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions. Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions. Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com. Special discount for YouTube and podcast listeners 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may Subscribe now using coupon code: PODCAST25.  Not ready to subscribe, sign up for a 15-day free trial.

Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.